Trials / Enrolling By Invitation
Enrolling By InvitationNCT07262268
A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations
- Status
- Enrolling By Invitation
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-7000 | Participants will take blinded investigational product (IP) orally once daily |
| DRUG | Placebo | Matching placebo taken orally once daily |
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2025-12-03
- Last updated
- 2026-04-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07262268. Inclusion in this directory is not an endorsement.